Healthcare organizations face a constant tension between driving antimicrobial stewardship and managing tight operational budgets. With antimicrobial resistance (AMR) tied to 2.8 million infections in the US each year, stewardship is a critical priority.1 Yet broad-spectrum antibiotics are routinely initiated before diagnostic results are available, increasing treatment duration and exposure. While procalcitonin (PCT) testing is often scrutinized as an upfront laboratory expense, evaluating it solely through a siloed lab budget overlooks its broader health system and patient care value. When integrated into structured clinical protocols, PCT-guided decision making can provide care teams with objective data for timely antibiotic de-escalation, helping health systems optimize resource utilization and total cost of care while optimizing quality and patient safety.
Using PCT to Support Antibiotic Stewardship
Because the signs and symptoms of bacterial infections frequently overlap with viral and non-infectious conditions, clinicians are often forced to initiate empirical therapy under high diagnostic uncertainty. In these scenarios, procalcitonin (PCT), C-reactive protein (CRP) and lactate offer complementary insights into disease pathophysiology and patient response kinetics.
Procalcitonin can be an effective biomarker for evaluating systemic bacterial infections and monitoring treatment response. Clinical trials and meta-analyses demonstrate that PCT-guided protocols may reduce overall antibiotic exposure which can shorten prescribing duration by two to three days in acute respiratory infections without compromising clinical outcomes.2,3
Building on the clinical impact, multiple health economic models across the US and Europe project that integrating PCT testing can help lower total cost of care per patient.4-6 Monitoring PCT alongside arterial blood gases and rapid blood cultures gives clinicians objective data that informs de-escalation decisions, and when appropriate, transition patients out of critical care. Additionally, reducing broad-spectrum antibiotic exposure protects native gut flora, with studies showing up to a 40% decrease in hospital-onset Clostridioides difficile (C. diff) rates.7 Ultimately, these downstream benefits allow health systems to bridge the gap between initial lab investment and enterprise-wide value.
More Testing is Not Always Better Stewardship
Successful PCT implementation extends beyond rolling out a new laboratory test. When ordered indiscriminately or interpreted in isolation, additional testing risks driving up expenditure without improving antibiotic utilization. Maximizing clinical value relies on establishing a collaborative, protocol-driven framework that engages pharmacists, clinicians, lab leadership, and quality teams to guide ordering, interpretation, and ongoing monitoring. A well-designed operational strategy focuses on three core pillars:
- Defined patient populations: Establish clear clinical criteria identifying which patient populations and clinical scenarios benefit most from PCT testing, accounting for variance across specific assay indications.
- EHR-integrated order sets: Embed serial testing guidance directly into electronic order sets to standardize ordering frequency, improve clinical adherence, and prevent unnecessary testing.
- Decision guidance: Pair results with clear interpretation guidance that informs antibiotic initiation or de-escalation rather than treating the assay as an isolated lab value.
The impact of PCT stewardship is best measured not by test volume, but by its alignment with overarching quality goals. Evaluating success involves tracking cross-functional metrics including antibiotic days of therapy, adverse event rates, length of stay, and total cost of care. Bringing laboratory leadership, pharmacy, antimicrobial stewardship, healthcare finance, and the clinical team together around these metrics helps ensure diagnostic utilization directly supports clinical excellence.
Aligning Lab Values with System Outcomes
Evaluating the true impact of procalcitonin testing requires looking beyond immediate laboratory acquisition costs. When embedded within a collaborative stewardship strategy that unites laboratory leadership, pharmacists, infectious disease specialists, and quality leaders, PCT testing can become a powerful tool for optimizing patient and health-system efficiency. For organizations evaluating or expanding PCT utilization, success ultimately hinges on integration that ensures tests are ordered within clear clinical protocols, interpreted in context, and tied to measurable clinical goals. Tracking key metrics such as therapy duration, length of stay, and de-escalation rates helps organizations continually validate performance and refine order sets. By leveraging diagnostic data to inform actionable clinical decisions, health systems can protect vital pharmacologic and laboratory resources while strengthening system efficiency and helping to preserve sustainable financial health.
References
- Antimicrobial Resistance Facts and Stats. Accessed October 8, 2026. https://www.cdc.gov/antimicrobial-resistance/data-research/facts-stats/index.html
- Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3
- Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066. doi:10.1001/jama.2009.1297
- Kip MM, Kusters R, IJzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015;18(11):944-953. doi:10.3111/13696998.2015.1064934
- Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS One. 2019;14(4):e0214222. Published 2019 Apr 23. doi:10.1371/journal.pone.0214222
- Steuten L, Mewes J, Lepage-Nefkens I, Vrijhoef H. Is Procalcitonin Biomarker-Guided Antibiotic Therapy a Cost-Effective Approach to Reduce Antibiotic Resistant and Clostridium difficile Infections in Hospitalized Patients?. OMICS. 2018;22(9):616-625. doi:10.1089/omi.2018.0040
- Kazakova SV, Baggs J, Yi SH, et al. Associations of facility-level antibiotic use and hospital-onset Clostridioides difficile infection in US acute-care hospitals, 2012–2018. Infection Control & Hospital Epidemiology. 2021;43(8):1067-1069. doi:10.1017/ice.2021.151
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
